Baker BROS. Advisors LP Makes New Investment in 4D Molecular Therapeutics, Inc. $FDMT

Baker BROS. Advisors LP acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the fourth quarter, Holdings Channel reports. The firm acquired 475,737 shares of the company’s stock, valued at approximately $3,568,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth $41,000. AQR Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth $46,000. Daiwa Securities Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth $48,000. Institutional investors own 99.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on FDMT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Chardan Capital reissued a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Stock Up 8.7%

Shares of 4D Molecular Therapeutics stock opened at $9.42 on Thursday. The stock’s fifty day moving average is $9.44 and its 200-day moving average is $9.14. The firm has a market capitalization of $492.48 million, a PE ratio of -3.67 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a 12-month low of $3.68 and a 12-month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Analysts expect that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.